An entrepreneur and the proprietor of the technology business Future Shop, Shaher Handous has worked in a variety of industries since coming to Canada from Lebanon. Among his business interests are aviation, commodities trading, and medical services and consulting. Committed to supporting his local community, Shaher Handous supports Stollery Children’s Hospital.
Business executive Shaher Handous operates a trading company in Canada. A family man, he supports organizations such as Stollery Children’s Hospital Foundation. The foundation works to advance healthcare technology and provide premium pediatric care. As a supporter, Shaher Handous and other donors contribute to Stollery in several ways. Miracle Maker – This option at Stollery consists of a monthly donation program. Interested donors sign up using their bank accounts or credit cards, and Stollery automatically deducts the designated funds each month. Securities and Stocks – Donating securities and stocks is a great gift option for donors who want to contribute and also avoid costly capital gains taxes in the future. By donating stocks or securities directly to Stollery, donors actually receive a charitable tax receipt at the end of the year instead. Memorial Gift – A memorial gift is one of the most personal ways to give to Stollery. Donors who have lost loved ones create funds in the names of loved ones and make donations in their memory. Donors can set up memorial funds online at www.stollerykids.com.
An entrepreneur and former salesman, Shaher Handous utilizes his business talents in a number of areas. For instance, as a communications specialist in the medical industry, Shaher Handous has expanded public knowledge about a medical treatment known as the Edmonton Protocol. Co-developed by Dr. Jonathan Lakey, the Edmonton Protocol is a medical treatment plan for individuals with type 1 diabetes that involves the transplantation of the islets of Langerhans, which are located within the pancreas. In diabetic patients, the beta cells in these endocrine-producing regions do not function normally, and insulin is not produced properly. During the procedure, the surgeon anesthetizes the patient and uses a catheter to inject islet cells from a donor into the portal vein. Once administered, the cells travel through the circulatory system into the liver, where they develop a new blood supply and begin to produce insulin. After the procedure, the number of working beta cells that can manufacture insulin is increased. People with diabetes who agree to the transplant then continue to take insulin until their systems adjust to the added cells. While these individuals will typically depend on diabetes medicine after the procedure, the need is reduced, as the glucose in the blood is better regulated.
Based in Edmonton, Alberta, Shaher Handous is a business executive who has managed several trading companies throughout the course of his career. Shaher Handous works alongside Jonathan Lakey, who co-developed a Type 1 diabetes treatment. Diabetes is a metabolic disorder that occurs when the body does not produce enough insulin. As a result, cells cannot absorb glucose, the main source of fuel for the body, and glucose builds up in the body to dangerous levels. Both Type 1 and Type 2 diabetes are potentially dangerous disorders. Type 1 diabetes is an autoimmune disease because the person’s body is responsible for killing the insulin-producing cells. Typically, this form of diabetes develops before the age of 40 and is not preventable. People with Type 1 diabetes must take insulin regularly, or the condition becomes life threatening. On the other hand, people with Type 2 diabetes suffer from low insulin production or insulin resistance or both. Approximately 85 percent of people suffering from diabetes have Type 2, and many people who develop it have pre-disposing factors, such as obesity and low activity levels.